Novel roles of Akt and mTOR in suppressing TGF-β/ALK5-mediated Smad3 activation

EMBO Journal

Volumn 25, Issue 1, 2006, Pages 58-69

  Song, Kyung ^a   Wang, Hui ^a   Krebs, Tracy L ^a   Danielpour, David ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Akt; IGF I; mTOR; PKB; Prostate; Rapamycin; Smad

Indexed keywords

ADENOVIRUS VECTOR; BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN FKBP12; PROTEIN KINASE B; RAPAMYCIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; ENZYME ACTIVITY; ENZYME REPRESSION; HUMAN; HUMAN CELL; MOLECULAR MODEL; MYRISTYLATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; WILD TYPE;

ACTIVIN RECEPTORS, TYPE I; ANIMALS; APOPTOSIS; CELLS, CULTURED; HUMANS; MUTATION; PHOSPHORYLATION; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, SMALL INTERFERING; SIROLIMUS; SMAD2 PROTEIN; SMAD3 PROTEIN; TACROLIMUS BINDING PROTEIN 1A; TRANSFORMING GROWTH FACTOR BETA;

ADENOVIRIDAE; ANIMALIA; MAMMALIA;

EID: 30444434212     PISSN: 02614189     EISSN: 14602075     Source Type: Journal    
DOI: 10.1038/sj.emboj.7600917     Document Type: Article

References (47)

1. Abdollah S, Macias-Silva M, Tsukazaki T, Hayashi H, Attisano L, Wrana JL (1997) TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling. J Biol Chem 272: 27678-27685
2. Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4: 335-348
3. Chan S (2004) Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 91: 1420-1424
4. Charng MJ, Kinnunen P, Hawker J, Brand T, Schneider MD (1996) FKBP-12 recognition is dispensable for signal generation by type I transforming growth factor-beta receptors. J Biol Chem 271: 22941-22944
5. Chipuk JE, Cornelius SC, Pultz NJ, Jorgensen JS, Bonham MJ, Kim SJ, Danielpour D (2002) The androgen receptor represses transforming growth factor-beta signaling through interaction with Smad3. J Biol Chem 277: 1240-1248
6. Conery AR, Cao Y, Thompson EA, Townsend Jr CM, Ko TC, Luo K (2004) Akt interacts directly with Smad3 to regulate the sensitivity to TGF-beta induced apoptosis. Nat Cell Biol 6: 366-372
7. Danielpour D, Kadomatsu K, Anzano MA, Smith JM, Sporn MB (1994) Development and characterization of nontumorigenic and tumorigenic epithelial cell lines from rat dorsal-lateral prostate. Cancer Res 54: 3413-3421
8. Danielpour D (1996) Induction of transforming growth factor-beta autocrine activity by all-trans-retinoic acid and 1 alpha, 25-dihydroxyvitamin D3 in NRP-152 rat prostatic epithelial cells. J Cell Physiol 166: 231-239
9. Danielpour D (1999) Transdifferentiation of NRP-152 rat prostatic basal epithelial cells toward a luminal phenotype: regulation by glucocorticoid, insulin-like growth factor-I and transforming growth factor-beta. J Cell Sci 112: 169-179
10. Danielpour D (2005) Functions and regulation of transforming growth factor-beta (TGF-beta) in the prostate. Eur J Cancer 41: 846-857
11. Downward J (1998) Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 10: 262-267
12. Fingar DC, Blenis J (2004) Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23: 3151-3171
13. Gao X, Zhang Y, Arrazola P, Hino O, Kobayashi T, Yeung RS, Ru B, Pan D (2002) Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol 4: 699-704
14. Grimberg A (2003) Mechanisms by which IGF-I may promote cancer. Cancer Biol Ther 2: 630-635
15. Guo Y, Kyprianou N (1999) Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Cancer Res 59: 1366-1371
16. Hayward SW, Haughney PC, Lopes ES, Danielpour D, Cunha GR (1999) The rat prostatic epithelial cell line NRP-152 can differentiate in vivo in response to its stromal environment. Prostate 39: 205-212
17. Hsing AY, Kadomatsu K, Bonham MJ, Danielpour D (1996) Regulation of apoptosis induced by transforming growth factor-beta1 in nontumorigenic rat prostatic epithelial cell lines. Cancer Res 56: 5146-5149
18. Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ (2002) Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 16: 771-780
19. Jetzt A, Howe JA, Horn MT, Maxwell E, Yin Z, Johnson D, Kumar CC (2003) Adenoviral-mediated expression of a kinase-dead mutant of Akt induces apoptosis selectively in tumor cells and suppresses tumor growth in mice. Cancer Res 63: 6697-6706
20. Manning BD, Cantley LC (2003) United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem Soc Trans 31: 573-578
21. Massague J (1992) Receptors for the TGF-beta family. Cell 69: 1067-1070
22. Megyesi K, Kahn CR, Roth J, Neville Jr DM, Nissley SP, Humbel RE, Froesch ER (1975) The NSILA-s receptor in liver plasma membranes. Characterization and comparison with the insulin receptor. J Biol Chem 250: 8990-8996
23. Nicholson KM, Anderson NG (2002) The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14: 381-395
24. Plas DR, Thompson CB (2003) Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J Biol Chem 278: 12361-12366
25. Rao RD, Buckner JC, Sarkaria JN (2004) Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents. Curr Cancer Drug Targets 4: 621-635
26. Remy I, Montmarquette A, Michnick SW (2004) PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3. Nat Cell Biol 6: 358-365
27. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding Protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363: 1346-1353
28. Roberts AB, Sporn MB (1990) The Transforming Growth Factor Beta. New York: Springer-Verlag
29. Rosenfeld RG, Hintz RL (1980) Characterization of a specific receptor for somatomedin C (SM-C) on cultured human lymphocytes: evidence that SM-C modulates homologous receptor concentration. Endocrinology 107: 1841-1848
30. Sarbassov dos D, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101
31. Seoane J, Le HV, Shen L, Anderson SA, Massague J (2004) Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117: 211-223
32. Song K, Cornelius SC, Danielpour D (2003a) Development and characterization of DP-153, a nontumorigenic prostatic cell line that undergoes malignant transformation by expression of dominant-negative transforming growth factor beta receptor type II. Cancer Res 63: 4358-4367
33. Song K, Cornelius SC, Reiss M, Danielpour D (2003b) Insulin-like growth factor-I inhibits transcriptional responses of transforming growth factor-beta by phosphatidylinositol 3-kinase/Akt-dependent suppression of the activation of Smad3 but not Smad2. J Biol Chem 278: 38342-38351
34. Stewart LV, Song K, Hsing AY, Danielpour D (2003) Regulation of trespin expression by modulators of cell growth, differentiation, and apoptosis in prostatic epithelial cells. Exp Cell Res 284: 301-313
35. Stockwell BR, Schreiber SL (1998) TGF-beta-signaling with small molecule FKBP12 antagonists that bind myristoylated FKBP12-TGF-beta type I receptor fusion proteins. Chem Biol 5: 385-395
36. Tang B, de Castro K, Barnes HE, Parks WT, Stewart L, Bottinger EP, Danielpour D, Wakefield LM (1999) Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells. Cancer Res 59: 4834-4842
37. Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J (2003) Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 13: 1259-1268
38. ten Dijke P, Miyazono K, Heldin CH (1996) Signaling via heterooligomeric complexes of type I and type II serine/threonine kinase receptors. Curr Opin Cell Biol 8: 139-145
39. Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL (1998) SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell 95: 779-791
40. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501
41. Wakefield LM, Roberts AB (2002) TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 12: 22-29
42. Wang H, Song K, Sponseller TL, Danielpour D (2005) Novel function of androgen receptor-associated protein 55/Hic-5 as a negative regulator of Smad3 signaling. J Biol Chem 280: 5154-5162
43. Wieser R, Wrana JL, Massague J (1995) GS domain mutations that constitutively activate T beta R-I, the downstream signaling component in the TGF-beta receptor complex. EMBO J 14: 2199-2208
44. Wu RY, Zhang Y, Feng XH, Derynck R (1997) Heteromeric and homomeric interactions correlate with signaling activity and functional cooperativity of Smad3 and Smad4/DPC4. Mol Cell Biol 17: 2521-2528
45. Xiao Z, Liu X, Lodish HF (2000) Importin beta mediates nuclear translocation of Smad 3. J Biol Chem 275: 23425-23428
46. Xu G, Zhang W, Bertram P, Zheng XF, McLeod H (2004) Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol 24: 893-900
47. Yamaguchi H, Wang HG (2001) The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene 20: 7779-7786